Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate
Source: SeekingAlpha
2025-11-13 21:22:09 ET
More on Trevi Therapeutics
- Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
- Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- Trevi spikes as B. Riley reportedly cites deal prospects
- Seeking Alpha’s Quant Rating on Trevi Therapeutics
- Historical earnings data for Trevi Therapeutics
Read the full article on Seeking Alpha
For further details see:
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate
Trevi Therapeutics Inc.
NASDAQ: TRVI
TRVI Trading
-0.57% G/L:
$10.9377 Last:
439,888 Volume:
$11.22 Open:
TRVI Latest News
March 10, 2026 04:05:00 pm
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
March 09, 2026 07:30:00 am
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
February 17, 2026 07:30:00 am
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
TRVI Stock Data
$1,448,359,364
104,764,019
0.7%
59
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
